48
Participants
Start Date
January 31, 2007
Primary Completion Date
June 30, 2008
Study Completion Date
August 31, 2008
Zelapar
Switch from oral selegiline to Zelapar 1.25 mg QD titrated to 2.5 mg QD
Stuart Isaacson, MD at Parkinson's Disease and Movement Disorder Center of Boca Raton, Boca Raton
R. Malcolm Stewart, MD at Neurology Specialists of Dallas, Dallas
PDCMDC 6550 Fannin, Suite 1801, Houston
Dee Silver, MD at Coastal Neurological Medical Group, Inc, La Jolla
James Tetrud, MD at The Parkinson's Institute, Sunnyvale
Baylor College of Medicine
OTHER